High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia.
Adult
Biopsy
Early Detection of Cancer
/ methods
Female
Gastritis
/ pathology
Healthy Volunteers
Helicobacter Infections
/ pathology
Helicobacter pylori
Humans
Intestines
/ pathology
Male
Metaplasia
/ pathology
Middle Aged
Pilot Projects
Precancerous Conditions
/ pathology
Risk Assessment
Risk Factors
Severity of Illness Index
Stomach Neoplasms
/ diagnosis
Gastric cancer
OLGA
OLGIM intestinal metaplasia
Risk stratification
Subtypes
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
18
11
2020
accepted:
04
05
2021
revised:
02
05
2021
pubmed:
16
5
2021
medline:
29
10
2021
entrez:
15
5
2021
Statut:
ppublish
Résumé
The use of Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastritis Assessment based on Intestinal Metaplasia (OLGIM) staging system is recommended for identifying subjects at risk for developing gastric cancer; usually high-risk lesions are considered only as stages III and IV. Accumulating evidence suggests that incomplete intestinal metaplasia (IM) is important in the development of gastric cancer. Our aim has been to identify the prevalence of incomplete IM in patients with low-risk OLGA/OLGIM stages among a high-risk general population. Healthy adult volunteers aged 40-64 years were invited to undergo upper endoscopy within a regional GISTAR pilot study in Kazakhstan (n = 166). Gastric lesions were staged according to OLGA/OLGIM staging system. High iron diamine-alcian blue (HID-AB) was used for subtyping IM. IM prevalence overall was 45.8%. Incomplete IM was present in 52.6% (type II in 30.3% and type III in 22.3%), whereas complete IM was found in 47.4% individuals. The prevalence of OLGIM I and II stage were 39.8 and 4.8%, respectively, whereas OLGIM III was observed in 1.2%. The prevalence of incomplete IM in patients stratified to OLGIM I was 54.5% (type II in 31.8% and type III in 22.7%). High prevalence of incomplete IM was detected not only in subjects with extensive IM, but in those stratified as at the OLGIM I stage. Without IM subtyping, patients with high risk of gastric cancer development would be missed for surveillance.
Identifiants
pubmed: 33990867
doi: 10.1007/s00428-021-03116-3
pii: 10.1007/s00428-021-03116-3
pmc: PMC8740520
mid: NIHMS1764574
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
679-686Subventions
Organisme : NCI NIH HHS
ID : P01 CA028842
Pays : United States
Organisme : Latvijas Universitate
ID : 6012-A53/65
Organisme : NIDDK NIH HHS
ID : P30 DK058404
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA116087
Pays : United States
Organisme : State Education Development Agency Republic of Latvia
ID : 1.1.1.1/18/A/184
Organisme : Ministry of Education and Science of the Republic of Kazakhstan
ID : AP05133849
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
BMJ Open. 2017 Aug 11;7(8):e016999
pubmed: 28801429
Int J Cancer. 2010 Dec 1;127(11):2654-60
pubmed: 20178099
JAMA. 2004 Jan 14;291(2):187-94
pubmed: 14722144
Asian Pac J Cancer Prev. 2014;15(18):7763-8
pubmed: 25292060
Asian Pac J Cancer Prev. 2021 Feb 01;22(2):597-602
pubmed: 33639679
Hum Pathol. 2006 Nov;37(11):1489-97
pubmed: 16949645
Asian Pac J Cancer Prev. ;17(12):5159-5164
pubmed: 28124881
Gastrointest Endosc. 2016 Oct;84(4):618-24
pubmed: 26995689
Gastrointest Endosc. 2009 Jul;70(1):18-25
pubmed: 19249770
Scand J Gastroenterol. 2010 Sep;45(9):1048-58
pubmed: 20509752
Virchows Arch. 2014 Apr;464(4):403-7
pubmed: 24477629
Indian J Gastroenterol. 2009 Mar-Apr;28(2):49-52
pubmed: 19696988
Gut. 2019 Jan;68(1):11-17
pubmed: 29306868
Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):205-23
pubmed: 23809241
Aliment Pharmacol Ther. 2002 Jul;16(7):1249-59
pubmed: 12144574
Gut. 1991 Oct;32(10):1110-3
pubmed: 1955163
Hepatogastroenterology. 2010 Nov-Dec;57(104):1563-6
pubmed: 21443121
Zhonghua Yi Xue Za Zhi (Taipei). 2001 Jun;64(6):331-6
pubmed: 11534800
BMJ. 2015 Jul 27;351:h3867
pubmed: 26215280
Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1128-33
pubmed: 20410824
Gut. 2007 Dec;56(12):1665-70
pubmed: 17698860
Endoscopy. 2019 Apr;51(4):365-388
pubmed: 30841008
J Gastroenterol Hepatol. 2009 Jan;24(1):140-8
pubmed: 18713298
Int J Cancer. 2013 Sep 1;133(5):1023-32
pubmed: 23280711
Gastroenterology. 2020 Feb;158(3):693-702
pubmed: 31816298
J Clin Pathol. 2004 Feb;57(2):177-82
pubmed: 14747445
Int J Cancer. 1994 May 1;57(3):324-9
pubmed: 8168991
Anticancer Res. 2013 Oct;33(10):4595-602
pubmed: 24123036
Gastroenterology. 2020 Feb;158(3):705-731.e5
pubmed: 31816300
J Gastroenterol Hepatol. 2016 May;31(5):953-8
pubmed: 26630310
Asian Pac J Cancer Prev. 2019 Dec 01;20(12):3825-3829
pubmed: 31870128
Gastroenterology. 2020 Feb;158(3):745-750
pubmed: 31887261
Aliment Pharmacol Ther. 2013 Nov;38(10):1292-302
pubmed: 24134499
Am J Gastroenterol. 2010 Mar;105(3):493-8
pubmed: 20203636
Gastroenterology. 2010 Dec;139(6):1894-1901.e2; quiz e12
pubmed: 20727889
Eur J Gastroenterol Hepatol. 2014 Apr;26(4):378-87
pubmed: 24569821
Dig Liver Dis. 2008 May;40(5):355-60
pubmed: 18291729
Gut. 1990 Oct;31(10):1097-104
pubmed: 2083854
Int J Cancer. 1999 Nov 26;83(5):615-9
pubmed: 10521796
Gastroenterology. 2008 Apr;134(4):945-52
pubmed: 18395075
Cancer. 1990 Aug 15;66(4):689-94
pubmed: 2386900
Cancer Res. 1990 Aug 1;50(15):4731-6
pubmed: 2369747
Eur J Cancer Prev. 2001 Aug;10(4):307-12
pubmed: 11535872